Skip to content
DataLookout
Menu

SAVID-SLDNCT07530419

Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words Show 7 more changesShow less
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Primary completion moved earlier from Dec 30, 2026 to Oct 7, 2026
    • Study completion pushed from Feb 28, 2027 to Dec 30, 2027
    • Start date changed from estimate of Apr 10, 2026 to Apr 24, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description revised
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Correlation between Samsung S-Viscosity and Canon Dispersion Slope
Timeframe: At the time of single study visit (Day 0)
Inter-vendor agreement (Bland-Altman analysis)
Timeframe: At the time of single study visit (Day 0)

Secondary (5)

Normal reference range of viscoelasticity parameters
Inter-cohort comparison of viscoelasticity parameters
Modified US-FAST score performance (exploratory)
Reproducibility of viscoelasticity measurements
Technical success rate

Arms and interventions

Cohort A: Healthy Reference (Living-donor candidates)

Adult living-donor candidates undergoing donor evaluation at SNUH. Confirmed hepatic steatosis \<5%, normal AST/ALT, and absence of chronic liver disease. Participation does not affect donor candidacy decisions.

Cohort B: Low MASH Risk MASLD (Rule-out)

Adults with sonographically suspected or confirmed hepatic steatosis classified post-hoc as low MASH risk by satisfying ALL three criteria: LSM \<6.82 kPa AND DeepUSFF \<7.86% (\<S1) AND AST ≤40 U/L (institutional ULN).

Cohort C: At-Risk MASH MASLD (Rule-in)

Adults with sonographically suspected or confirmed hepatic steatosis classified post-hoc as at-risk MASH by satisfying mandatory LSM ≥6.82 kPa (suggestive of ≥F2 significant fibrosis) AND at least one of: DeepUSFF ≥15.05% (≥S2) OR AST \>40 U/L. Participants meeting neither Cohort B nor Cohort C definitions are classified as 'Indeterminate' and analyzed as an exploratory subgroup.

Cohort D: Indeterminate Zone (Exploratory subgroup)

Adults with sonographically suspected or confirmed hepatic steatosis who do not meet the full criteria for either Cohort B (Low MASH risk) or Cohort C (At-risk MASH). This cohort primarily includes participants with DeepUSFF values in the S1 range (7.86% to \<15.05%), or those meeting only a subset of the Cohort B/C criteria. Cohort D is analyzed as a pre-specified exploratory subgroup and is not included in the primary stratified comparison between Cohort B and Cohort C. Descriptive statistics are reported separately.

Devices: Samsung Medison HERA W12 (R30) with S-Shearwave platform, Canon Aplio i800 with Dispersion Slope Imaging

Sites

1 site in 1 country

  • Seoul National University HospitalSeoul, South Korea